Strategies and challenges for the next generation of antibody-drug conjugates (Q39182945)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 17 March 2017

Language	Label	Description	Also known as
English	Strategies and challenges for the next generation of antibody-drug conjugates	scientific article published on 17 March 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Strategies and challenges for the next generation of antibody-drug conjugates (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1 reference

based on heuristic

inferred from title

Charles Dumontet

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Alain Beck

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Liliane Goetsch

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Nathalie Corvaïa

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

17 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

315-337

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Antibody-drug conjugates: current status and future directions

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Brentuximab vedotin.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Maturing antibody-drug conjugate pipeline hits 30.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-drug conjugates: present and future

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

The cryptophycins as potent payloads for antibody drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Microtubule-binding agents: a dynamic field of cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-drug conjugates: an emerging concept in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

TP53 loss creates therapeutic vulnerability in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate-dependent dioxygenase.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Potent antibody drug conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-drug conjugates: targeted drug delivery for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Cell killing by antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Brentuximab Vedotin (SGN-35).

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Strategies and challenges for the next generation of therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Characterization of therapeutic antibodies and related products.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

The INNs and outs of antibody nonproprietary names

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Rethinking the INN system for therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Conformational difference in human IgG2 disulfide isoforms revealed by hydrogen/deuterium exchange mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Marketing approval of mogamulizumab: a triumph for glyco-engineering

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Design and application of antibody cysteine variants.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Improving the serum stability of site-specific antibody conjugates with sulfone linkers

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Methods to Make Homogenous Antibody Drug Conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A general approach to site-specific antibody drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

The covalent structure of an entire gammaG immunoglobulin molecule

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Site-specific antibody-drug conjugation through glycoengineering.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Covalent Chemical Ligation Strategy for Mono- and Polyclonal Immunoglobulins at Their Nucleotide Binding Sites

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Long-term stabilization of maleimide-thiol conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

2-(Maleimidomethyl)-1,3-Dioxanes (MD): a Serum-Stable Self-hydrolysable Hydrophilic Alternative to Classical Maleimide Conjugation

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-targeted drugs and drug resistance--challenges and solutions.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Mechanisms of Resistance to Antibody-Drug Conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Emerging formats for next-generation antibody drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-drug conjugates for non-oncological indications.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

An immunosuppressive antibody-drug conjugate

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Novel antibody-antibiotic conjugate eliminates intracellular S. aureus

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I - Optimization of separation conditions

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. II- Identification of sub-units for the char

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Characterization of therapeutic antibodies and related products by two-dimensional liquid chromatography coupled with UV absorbance and mass spectrometric detection

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Characterization of cetuximab Fc/2 dimers by off-line CZE-MS.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Why is it so difficult to use gemtuzumab ozogamicin?

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Site-specific antibody drug conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Effect of attachment site on stability of cleavable antibody drug conjugates.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

21 January 2018

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Computational selection of antibody-drug conjugate targets for breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Therapeutic antibodies and derivatives: from the bench to the clinic

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

2015 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Prognostic value of S-phase cells in AML patients

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

Investigation of Optical Coherence Microelastography as a Method to Visualize Cancers in Human Breast Tissue.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.268

31 March 2020

The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/28303026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies in myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28303026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/28303026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

1 reference

https://pubmed.ncbi.nlm.nih.gov/28303026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/28303026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The next generation of antibody-drug conjugates comes of age

1 reference

https://pubmed.ncbi.nlm.nih.gov/28303026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRD.2016.268

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Dimensions Publication ID

0 references

release_lo6kvg7k4fgfvodd4sww2a2dqy

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303026%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39182945&oldid=2202653221"